Op2Lysis new thrombolytic agent patent to be granted in Europe

Op2Lysis new thrombolytic agent patent to be granted in Europe

Receipt of a decision to grant a patent from the European Patent Office for a strategic patent application related to Op2Lysis O2L-001 program for hemorrhagic stroke patients.

See the press release below

About the author

Jérôme PARCQ administrator